Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax RateWages, Salaries and Other
Others
Ratios

Ptc Therapeutics (PTCT) Research & Development (2016 - 2025)

Ptc Therapeutics (PTCT) has 14 years of Research & Development data on record, last reported at $133.1 million in Q4 2025.

  • For Q4 2025, Research & Development rose 6.7% year-over-year to $133.1 million; the TTM value through Dec 2025 reached $528.3 million, down 1.16%, while the annual FY2025 figure was $455.2 million, 14.82% down from the prior year.
  • Research & Development reached $133.1 million in Q4 2025 per PTCT's latest filing, up from $109.0 million in the prior quarter.
  • Across five years, Research & Development topped out at $195.1 million in Q1 2023 and bottomed at $109.0 million in Q1 2025.
  • Average Research & Development over 5 years is $146.4 million, with a median of $137.3 million recorded in 2021.
  • Peak YoY movement for Research & Development: surged 147.09% in 2021, then tumbled 40.48% in 2024.
  • A 5-year view of Research & Development shows it stood at $149.8 million in 2021, then rose by 25.93% to $188.7 million in 2022, then crashed by 35.69% to $121.4 million in 2023, then grew by 2.82% to $124.8 million in 2024, then grew by 6.7% to $133.1 million in 2025.
  • Per Business Quant database, its latest 3 readings for Research & Development were $133.1 million in Q4 2025, $109.0 million in Q1 2025, and $124.8 million in Q4 2024.